SNORA68: A Potential Drug Target for Cancer and Other Diseases

Target Name: SNORA68

NCBI ID: G26780

SNORA68

Other Name(s): U68 | SNORA68A | small nucleolar RNA, H/ACA box 68 | Small nucleolar RNA, H/ACA box 68 | RNU68

SNORA68: A Potential Drug Target for Cancer and Other Diseases

SNORA68 (U68) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the superfamily of N-cadherin-related genes (NCRG), which are known for their role in cell-cell adhesion and tissue organization. SNORA68 has been shown to play a role in several physiological processes in the body, including cell signaling, angiogenesis, and inflammation.

One of the key functions of SNORA68 is its role in cell signaling. It is a negative regulator of the protein tyrosine kinase (TK), which is a key enzyme involved in many signaling pathways in the body. When TK is activated, it can cause SNORA68 to become inactive, which can lead to the inhibition of cell signaling. In contrast, when TK is inhibited, SNORA68 becomes active, allowing it to regulate cell signaling.

Another function of SNORA68 is its role in angiogenesis. Angiogenesis is the process by which new blood vessels are formed in the body, and it is a critical process for the development and maintenance of tissues. SNORA68 has been shown to play a positive role in the regulation of angiogenesis by TK. It is a critical negative regulator of the TK/FAK-associated signaling pathway, which is involved in the regulation of angiogenesis.

In addition to its role in cell signaling and angiogenesis, SNORA68 is also involved in the regulation of inflammation. It is a negative regulator of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation. SNORA68 has been shown to play a role in the regulation of NF-kappa-B signaling by TK. In addition, it is also involved in the regulation of the production of pro-inflammatory cytokines by immune cells.

Given its involvement in several important physiological processes, SNORA68 is a potential drug target or biomarker. Many studies have suggested that inhibiting the activity of SNORA68 could be a useful therapeutic approach for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, several studies have shown that inhibiting the activity of SNORA68 can be effective in treating breast cancer, by inhibiting the growth and survival of cancer cells.

In addition to its potential therapeutic applications, SNORA68 is also a valuable research tool for the study of cell signaling and angiogenesis. Its expression has been shown to be regulated by a variety of factors, including TK, FAK, and NF-kappa-B. This makes it an attractive target for studies of the regulation of these factors, as well as the regulation of angiogenesis.

Overall, SNORA68 is a protein that plays a critical role in several important physiological processes in the body. Its function as a negative regulator of cell signaling, angiogenesis, and inflammation makes it a potential drug target or biomarker. Further research is needed to fully understand the role of SNORA68 in the regulation of these processes, as well as its potential therapeutic applications.

Protein Name: Small Nucleolar RNA, H/ACA Box 68

The "SNORA68 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA68 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets